. Anti-MUC1 aptamers: radiolabelling with 99mTc and biodistribution in MCF-7 tumour-bearing mice. Nuclear Medicine and Biology, 36(6) Tc, for the potential use as radiopharmaceuticals for diagnostic imaging of breast cancer.
2 labelled aptamers were separated from free 99m Tc using microcon filter separation and monitored by HPLC at all stages, to ensure that only radiolabelled aptamers were produced. The biodistribution properties of the two aptamer-radionuclide conjugates were analysed in MCF-7 tumour bearing mice and compared.
Results: Efficient and convenient labelling of the two aptamers with 99m Tc was achieved as the last step of the synthesis (post-conjugation labelling). Both the aptamer-chelator conjugates had strong 99m Tc binding properties and the resulting complexes were stable in vivo, both in terms of nuclease degradation and leaking of the metal. The radiolabelled aptamers showed a high renal clearance and a high uptake in the intestine. 
Conclusions

Introduction
MUC1 is a large, rode-like glycoprotein consisting of an N-terminus projecting away from the cell surface as a long filament made of tandem repeats, a transmembrane region and a C-terminus cytoplasmatic tail [1, 2] .
Its functions are those typically associated with mucins such as lubrication and hydration of cell surfaces as well as protection from microorganisms and degradative enzymes [2] .
MUC1 is widely expressed on normal epithelial tissues but when they become malignant, its expression is increased at least ten fold, and the glycosylation and distribution of the protein at the cell surface are modified. MUC1 is highly expressed by the majority of cancers and, in particular, by primary and metastatic breast cancers [3] [4] [5] [6] [7] [8] .
Molecular targeted radiotherapy is an area of continuing interest that has recently seen the approval of various radiolabelled antibodies for cancer therapy, particularly in the treatment of lymphoma and leukaemia [9] [10] [11] . However, the use of monoclonal antibodies (MAbs) as such therapeutic modalities has not been without significant problems, including the time period required to produce MAbs, their immunogenicity and size. The use of humanised antibodies has overcome the immunogenicity related problems, but this can further increase the cost and time of the antibody production.
Combinatorial chemistry techniques coupled with PCR amplification allows, through exponential enrichment, the evolution of DNA based molecules (aptamers) which can bind to almost any target, including extracellular proteins, antibodies, peptides and small molecules. Research on the rapid selection of aptamers based on the SELEX methodology forms the basis for the development of high affinity and specificity molecules, which bind to surface determinants of tumour cells [12] [13] [14] . The procedure is accomplished within a short period of time, compared with several months required for the selection and purification of specific monoclonal antibodies. Aptamers offer low immunogeniciy, good tumour penetration, rapid uptake and fast systemic clearance, which favour their application as effective vehicles for cytotoxic agents or 4 radioisotopes [15] [16] [17] [18] . To date few examples of radiolabelling of aptamers can be found in literature showing that aptamers can be used as targeting agents in imaging and in radio-therapy [19] [20] [21] . With regards to the potential efficacy of aptamers as targeted radiopharmaceuticals in cancer therapy, we have previously shown that aptamers have improved tumour penetration, when compared with antibodies [21] . It is speculated that radiolabelled aptamers would have great potential as imaging agents, given that the majority of the aptamer not bound to the tumour is cleared rapidly from the system. In comparison, intact radiolabelled antibodies remain in circulation for a very long time, often resulting in organ toxicity. On the other hand, for therapeutic applications, the small molecular weight, and the inherent hydrophilicity, would result in the majority of the aptamer being washed out of the system too rapidly. Thus, in therapeutic applications, aptamers will need to be modified, for example PEGylated, to improve their pharmacokinetic properties [20] .
The selection of high affinity and specificity DNA aptamers against the highly immunogenic epitope of the un-glycosilated protein core of the MUC1 glycoprotein [22] and for the malignant glycosilated form of MUC1 [23] as tumour markers on epithelial cancer cells has been previously reported.
A previous work has studied the labelling of the MUC1 protein core targeting aptamer (AptA) with 99m Tc. Various chelating agents have been conjugated to the aptamer and the biodistribution data of the labelled products showed differences depending on the size of the conjugate and on the type of ligand [21] .
We report the conjugation of the two different aptamers with MAG2, their efficient radiolabelling with 99m Tc, and subsequent biodistribution studies in MCF7 tumour bearing mice.
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Results and discussion
Conjugation
NHS activated S-Benzoyl-MAG2 was conjugated to the aptamers at pH=9.3. In the case of the coupling of S-Benzoyl-MAG2 to AptA the HPLC analysis of the reaction mixture showed a new peak eluting at 16.5 min while the un-conjugated AptA eluted at 15.1 min. (Fig. 1) . MALDI -MS analysis of the isolated new peak confirmed it as the desired S-Benzoyl-MAG2-AptA having a MW of 8160. The conjugation yield was 70-80% in the case of AptA and >80% for AptB.
HPLC analysis of S-Benzoyl-MAG2 and AptB reaction mixture showed the product and the un-conjugated AptB eluting respectively at 16.1 min and 14.5 min. (Fig. 1) MALDI-MS analysis of the isolated new peak showed a single product having the MW of 8301. The conjugation yield also in this case was high (>84%). The conjugation yields could be determined after confirming by UV-Vis calibration lines that the S-Benzoyl-MAG2 moiety does not contribute to the absorption of the conjugates at 260nm (data not shown).
Insert Fig. 1 here
FID Binding assay
Post-selection modifications on an aptamer can alter its original structure and overall charge and therefore its binding and affinity properties for the target.
The FID assay studies the displacement of [Ru(phen) 2 
DPPZ]
2+ from the aptamer due to the addition of the binding peptide [24] [25] [26] . AptA and MAG2-AptA, dissolved in the same solution previously used for the selection [22] , Tc-tartrate, having R t of 23.7 and 2.7 min respectively, were 7 detected. The radiolabelled aptamers were isolated from small molecular weight impurities by ultrafiltration using microcon 3kDa MWCO filters with a recovery of >80% of the radioactivity on the cartridge. HPLC analysis of the purified labelled products shows that >99% of the activity is associated to the aptamers (Fig. 3 ).
Insert Fig. 3 
Stability of 99m
Tc-labelled aptamers
Both the used aptamers where modified on the 3' end with an inverted thymidine to protect them from nuclease digestion [27] . Previous studies already showed the stability (non fragmentation) of the modified aptamers in serum up to 12 hours [21] .
The stability of the labelled aptamers was investigated in order to study the chelation strength of the molecule and to get an indication of the stability of the complex in vivo in relation to the possible leaking of the radionuclide.
After labelling and purification by ultrafiltration, the aqueous solutions containing the labelled aptamers were stored at room temperature and analysed by HPLC every hours up to 3 hours. Both Tc-aptamers showed a >98% radiochemical purity after three hours. The only impurity detectable was free pertechnetate. Each isolated labelled aptamer was then tested for the stability towards cysteine [28] .
The percentage of dissociation is ≤2% at molar ratios below 60:1 after 3 hours from the addition of the challenger. The instability increases to a value of 8.7% in the case of 99m
Tc-MAG2-AptA and 12% in the case of TcMAG2-AptB at molar ratio 5000:1 (Fig.4 ).
An activity of 55-65 MBq of the radio-labelled conjugates was added to 3 ml of human blood and the mix was incubated at 37ºC. The radiochemical purity was assessed by analyzing samples of plasma by ITLC using butanone as eluent every Insert Table 1 here   Insert Table 2 here Insert Fig. 6 here As expected, the main routes of excretion of both small aptamers was via the urinary tract and through the hepatobiliary system. Both aptamers show an excretion of more than 70% of the activity in urine and faeces after 3 hours, increasing to 99% after 22 hours. After 3h p.i., 14.3% of Tc radiolabelled MAG2 conjugated oligonucleotides [29, 30] . In general the two radiolabelled aptamers showed a similar distribution throughout the test animals.
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The accumulation of 99m
Tc-labelled aptamers in the tumour amounted to 0.051% ID/g (for AptA) and 0.044% ID/g (for AptB) after 3 hours p.i. The uptake increased to 0.12% ID/g (AptA) and 0.14% ID/g (AptB) at 5 h. After 22 h p.i., the activity decreased to 0.008% ID7g (AptA) and 0.013% ID/g (AptB) (Fig. 7) .
Insert Fig. 7 here
Radiolabelled AptB shows a slightly higher tumour uptake than AptA at 5 h after injection. The activity, on the other hand, was released quicker from the target in the The tumour uptake and clearance data showed a different behaviour between the two aptamers suggesting a quicker internalisation in the tumour cells of AptB than AptA.
The tumour/tissue ratios achieved in the present study will need to be improved before using the above described aptamers as clinical radiolabelled targeting agents.
Enhancement of their short circulating biological half-life could be a way to achieve that goal. The rapid kidney clearance of aptamers may be altered either by increasing their overall molecular weight by conjugation to PEG [20, 31] or by attaching them to the surface of carrier systems such as liposomes [32, 33] .
Acknowledgments
This study was conducted with financial support from the Breast Cancer Campaign.
We thank David Lambert and Dr Huma Kahn for assistance with the FID assay.
Elaine Blackshaw and Andrew McKenzie from the Nottingham University Hospital
and Clinical Science, University of Nottingham for providing MCF7 tumour xenografts and their expertise in biodistribution studies.
Experimental Section
Instrumentation and Materials
The two DNA aptamers (AptA and AptB) were synthesised by RNA-TEC (Leuven, [Ru(phen) 2 DPPZ](PF 6 ) 2 was synthesised according to literature [25] . The MUC1 core peptide (APDTRPAPG) was prepared using standard peptide coupling automated 
The technetium-labelled products were analysed by Waters LC Module1 RP-HPLC using a Phenomenex Gemini 5 µm C18 110A column (250x4.60mm, 5 µm) plus Gemini C18 4x3.0mm security guard cartridge (Phenomenex). The eluate was monitored by UV-detection at 260 nm and on-line radiochemical detection (Harwell 600) using the same eluents and gradient as before but at a flow rate of 1ml/min. The MAG2-aptamers and the radiolabelled conjugates were desalted by ultrafiltration using Microcon 3kDa MWCO cartridges (Millipore). Radiochemicalpurity was determined by ITLC using acetone as solvent on 1cm x 6cm strips of Whatman No 1 paper and scanned using a NaI(Tl) scintillation detector with a collimated lead slit The reaction was allowed to proceed under vortex mixing at room temperature for 2 hours.
After conjugation, the S-Benzoyl-MAG2-aptamers were purified by RP-HPLC. The isolated peaks were lyophilised and desalted using microcon cartridges (3kDa 
FID Binding Assay
A 50 nM solution of either AptA, MAG2-AptA or the control aptamer in 5mM The solution was allowed to cool down to room temperature before desalting using microcon cartridges (3kDa MWCO). The radiochemical purity was controlled by RP-HPLC.
Stability of 99m
Tc-labelled MAG2-aptamers in solution
After labelling, the reaction mixtures were desalted using microcon cartridges (3kDa MWCO). The resulting solutions were stored at room temperature and analysed by HPLC every hour up to 3 hours.
Stability of 99m
Tc-labelled MAG2-aptamers to excess of cysteine
To measure the stability of the A sample of blood (3 ml) with the same activity of 99m TcO 4 -was analysed as control.
R f plasma-pertechnetate= 0.5.
Biodistribution in mice
Groups 
